Sero-surveillance SARS-CoV-2

Serologic surveillance of SARS-CoV-2 during the 2020 pandemic in exposed and unexposed healthcare workers in an academic hospital in Amsterdam

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26401

Enrollment

800

Registered

2020-05-19

Start date

2020-03-23

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, humane coronaviruses NL63, 229E, OC43, HKU1

Interventions

none

Eligibility

Inclusion criteria

Inclusion criteria: Exposed group: nurses & physicians caring for suspected or confirmed current COVID-19 patients on a COVID-19 unit, ICU or emergency ward. Intermediate group: nurses & physicians caring for patients without suspected or confirmed current COVID-19 (in contrast to the other groups, this group is only measured once) Control group: hospital personnel not working in patient care

Exclusion criteria

Exclusion criteria: Age <18 years old.

Design outcomes

Primary

Measure	Time frame
prevalence and time to SARS-CoV-2 seroconversion (IgG and/or IgM) compared between groups. We will test for differences between groups (dichotomous & survival data), assuming a 10% minimally relevant difference. If groups are not statistically different we will use non-inferiority analysis methods to test whether the difference between groups is within the non-inferiority margin of 10%.	—

Secondary

Measure	Time frame
presence of non-SARS-CoV-2 coronavirus antibodies and its association with SARS-CoV-2 seroconversion and disease severity. Influence of self-reported exposure to COVID-19 patients as a continuous determinant on SARS-CoV-2 seroconversion.	—

Contacts

Public ContactJonne Sikkens

Amsterdam UMC

j.sikkens@amsterdamumc.nl0204444444

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)